The upcoming earnings report for BridgeBio Pharma, Inc. (BBIO) is scheduled for Monday, May 4th. Analysts anticipate a consensus estimate EPS of -0.71.
BridgeBio Pharma, Inc. (BBIO) experienced a price decline of $3.79, representing a -5.09% change from the previous close. The trading volume surged by 339.59% to $9.32 million compared to the average.
In the latest quarterly earnings report on Monday, February 23rd, BridgeBio Pharma, Inc. (BBIO) reported a consensus estimate EPS of -0.75.
The company reported a net change in cash of -$72.41 million, with operating cash flow at -$56.42 million. Notable figures include debt repayment of $8.56 million and free cash flow of -$60.95 million.
BridgeBio Pharma, Inc. (BBIO) generated revenue of $154.18 million with a gross profit of $138.76 million. Operating income was reported at -$185.24 million, resulting in a net income of -$197.24 million.
Key financial ratios indicate challenges, with negative profit margins and a high debt ratio of 291.52. Notable metrics include return on equity at 9.5% and a price-to-sales ratio of 97.85.
The balance sheet shows total assets of $936 million, including $753.68 million in total current assets. Total liabilities amount to $3 billion, with a net debt of $2.16 billion.
This comprehensive overview provides insight into BridgeBio Pharma, Inc.'s financial performance and upcoming earnings expectations.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.